Vista Pharmaceuticals Ltd. engages in the manufacture and market of pharmaceutical products. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2003-07-21. The firm also sells the products to its related companies, which are engaged in the manufacture of formulations. The company offers over-the-counter and prescription generic drug products, consisting of tablets, capsules and liquids covering various therapeutic categories. Its products include tablet dosage forms in the United States market, such as Sulfamethoxazole & Trimethoprim, Acetaminophen, Bismuth Subsalicylate, Bismuth Subgallate, Ferrous Gluconate, Ferrous Sulfate, Pyrantel Pamoate and Isoxsuprine HCl and tablet dosage forms in the non-United States market, such as Aspirin, Atenolol, Mebendazole, Nefidipine, Quinine Sulfate, Ranitidine HCl, Magnesium Trisilicate Compound, Aluminium Hydroxide, Folic Acid and Captopril. Its capsule dosage forms in the non-United States market include Indomethacin, Piroxicam and Nefidipine.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.
11 fields couldn't be derived. The company was scraped before the cash-flow and balance-sheet rows were captured. Re-running an analysis will refresh these.